Transethosome-based topical administration systems with enhanced penetration and dual actions for treating EGFR-overexpressed cutaneous squamous cell carcinoma

Transethosome-based topical administration systems with enhanced penetration and dual actions for treating EGFR-overexpressed cutaneous squamous cell carcinoma

Epidermal growth factor receptor (EGFR)-overexpressing cutaneous squamous cell carcinoma (CSCC) necessitates more effective therapies due to its elevated metastasis risk compared to the conventional CSCC. While photodynamic therapy (PDT) is a promising way to treat CSCC, effectively administering ph...

Full description

Bibliographic Details
Main Authors:	Wang, Wenyan, Tham, Phoebe Huijun, Ding, Chendi, Huang, Ping, Li, Tingxuan, Luo, Jingjing, Xiang, Huijing, Zeng, Xiaowei, Chen, Hongzhong, Zhao, Yanli
Other Authors:	School of Chemistry, Chemical Engineering and Biotechnology
Format:	Journal Article
Language:	English
Published:	2024
Subjects:	Medicine, Health and Life Sciences Cutaneous squamous cell carcinoma EGFR inhibitor
Online Access:	https://hdl.handle.net/10356/177932

Similar Items

The Effects of Association of Topical Polydatin Improves the Preemptive Systemic Treatment on EGFR Inhibitors Cutaneous Adverse Reactions
by: Mauro Bavetta, et al.
Published: (2021-01-01)

Macrophage targeting of nitazoxanide-loaded transethosomal gel in cutaneous leishmaniasis
by: Husna Khalid, et al.
Published: (2022-10-01)

Remodeling of dermal adipose tissue alleviates cutaneous toxicity induced by anti-EGFR therapy
by: Leying Chen, et al.
Published: (2022-03-01)

miR-27a Downregulation Promotes Cutaneous Squamous Cell Carcinoma Progression via Targeting EGFR
by: Yinghui Wang, et al.
Published: (2020-01-01)

Promotion of cutaneous penetration of nifedipine for nanoemulsion
by: Paula de Oliveira Arantes, et al.
Published: (2017-07-01)

How does EGFR overexpression affect the development and treatment of rectal cancer?
by: Monika A. Kozłowska-Geller, et al.
Published: (2018-12-01)

Disruptin, a cell-penetrating peptide degrader of EGFR
by: Ranjit K. Mehta, et al.
Published: (2021-08-01)

Improving the Efficacy of EGFR Inhibitors by Topical Treatment of Cutaneous Squamous Cell Carcinoma with miR-634 Ointment
by: Jun Inoue, et al.
Published: (2020-12-01)

A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance
by: Li Liu, et al.
Published: (2021-10-01)

Supramolecular Hydrogel-Wrapped Gingival Mesenchymal Stem Cells in Cutaneous Radiation Injury
by: Shasha Nie, et al.
Published: (2022-09-01)

Comprehensive profiling of EGFR mutation subtypes reveals genomic-clinical associations in non-small-cell lung cancer patients on first-generation EGFR inhibitors
by: Yongkang Bai, et al.
Published: (2023-04-01)

Lycorine transfersomes modified with cell-penetrating peptides for topical treatment of cutaneous squamous cell carcinoma
by: Ying Li, et al.
Published: (2023-04-01)

Case report: Response to Savolitinib/EGFR-TKI combination in NSCLC patients harboring concurrent primary MET amplification/overexpression and EGFR mutation
by: Xiaolin Ren, et al.
Published: (2024-02-01)

Case report: EGFR fusion mutation combined with EGFR amplification responds to EGFR-TKI therapy
by: Zhulin Wang, et al.
Published: (2024-03-01)

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
by: Wang Fen, et al.
Published: (2012-08-01)

Prognostic Role of EGFR/p-EGFR in Patients With Nasopharyngeal Carcinoma: A Meta-Analysis
by: Xishan Chen, et al.
Published: (2021-08-01)

Comparing the Effects of Topical Miltefosine and Glucantime in Treatment of Cutaneous Leishmaniasis
by: Ali Asilian, et al.
Published: (2014-03-01)

The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
by: Anna Maria Rachiglio, et al.
Published: (2019-03-01)

Screening of differentially expressed transcription factors in keratinocytes with overexpression of EGFR induced by rhPTH(1-34)
by: Wenqi ZHAO, et al.
Published: (2023-08-01)

Design and Evaluation of Engineered Extracellular Vesicle (EV)-Based Targeting for EGFR-Overexpressing Tumor Cells Using Monobody Display
by: Hiroaki Komuro, et al.
Published: (2022-01-01)

Overexpression of EGFR and TGFα in von Hippel–Lindau-Related Central Nervous System Hemangioblastomas
by: Zhen Liu, et al.
Published: (2020-05-01)

Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy
by: Diana B. Peckys, et al.
Published: (2021-11-01)

Treatment of cutaneous lupus with topical ruxolitinib cream
by: Jonathan J. Park, PhD, et al.
Published: (2022-10-01)

The Skin Side Effects of Topical Glucantime in Patients with Cutaneous Leishmaniasis
by: Mohammad Ali Nilforoushzadeh, et al.
Published: (2015-08-01)

Advances in the diagnosis and treatment of cutaneous T-cell lymphoma
by: Hongzhong JIN, et al.
Published: (2023-10-01)

Mechanisms of EGFR-TKI-Induced Apoptosis and Strategies Targeting Apoptosis in EGFR-Mutated Non-Small Cell Lung Cancer
by: Shigetoshi Nishihara, et al.
Published: (2022-11-01)

Expanding the Therapeutic Window of EGFR-Targeted PE24 Immunotoxin for EGFR-Overexpressing Cancers by Tailoring the EGFR Binding Affinity
by: Sei-Yong Jun, et al.
Published: (2022-12-01)

Transethosomal Gel for the Topical Delivery of Celecoxib: Formulation and Estimation of Skin Cancer Progression
by: Ahmed A. H. Abdellatif, et al.
Published: (2022-12-01)

The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors
by: Ikei S. Kobayashi, MD, PhD, et al.
Published: (2024-01-01)

Fixed cutaneous sporotrichosis treated with topical amphotericin B in an immune suppressed patient
by: Vikram K. Mahajan, et al.
Published: (2015-03-01)

Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases
by: Jinyao Zhang, et al.
Published: (2021-12-01)

Treatment of cutaneous leishmaniasis by topical 25% podophyllin solution (single, blinded, therapeutic, controlled study)
by: Khalifa E. Sharquie, et al.
Published: (2015-07-01)

Epidermal growth factor receptor (EGFR) overexpression in endometrial carcinoma: association with histopathologic parameters
by: Atif Ali Hashmi, et al.
Published: (2019-03-01)

Immunomodulatory effects of topical diphencyprone for the treatment of acute urban cutaneous leishmaniasis
by: Yalda Nahidi, et al.
Published: (2021-02-01)

Topical Treatment Modalities for Old World Cutaneous Leishmaniasis: A Review
by: R. Alavi-Naini, et al.
Published: (2012-01-01)

Mechanisms of resistance to EGFR-targeted therapies in colorectal cancer: more than just genetics
by: Christine Parseghian, et al.
Published: (2023-09-01)

Role of the Expression Level of Nrf2 in Predicting Response of EGFR-TKIs  in Lung Adenocarcinoma Patients with EGFR Gene Mutations
by: Xiang ZHU, et al.
Published: (2014-02-01)

Targeting Autophagy for Overcoming Resistance to Anti-EGFR Treatments
by: Yoojung Kwon, et al.
Published: (2019-09-01)

Research Progress of the Resistance Mechanism of Non-small Cell Lung Cancer  to EGFR-TKIs
by: Huihui LIU, et al.
Published: (2013-10-01)

Tumor-specific delivery of therapeutic siRNAs by anti-EGFR immunonanoparticles
by: Kim JS, et al.
Published: (2018-08-01)